IC
RVMD icon

Ikarian Capital’s Revolution Medicines RVMD Stock Holding History

Ikarian Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-163,142
Closed -$15.9M – 186
2026
Q1 		$15.9M Buy
163,142
+25,000
+18% +$2.52M 1.29% 19
2025
Q4 		$11M Buy
+138,142
New +$9.06M 0.86% 32

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Ikarian Capital's RVMD Position: Q2 2026 in Review

Ikarian Capital sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 163,142 shares — an estimated $15.9M sold.

Ikarian Capital first reported a position in RVMD in Q4 2025 and held it in 2 quarters. The position peaked at $15.9M in Q1 2026. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Ikarian Capital reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Ikarian Capital sold 163,142 Revolution Medicines shares in Q2 2026, an estimated $15.9M.
  • Ikarian Capital first reported a position in Revolution Medicines in Q4 2025 and held it in 2 quarters.
  • Ikarian Capital's Revolution Medicines position peaked at $15.9M in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.